Modulus Oncology

An innovative spin-out company created by a founding team of scientists from The University of Sheffield and successful biotech entrepreneurs. Modulus has developed first-in-class antagonists of a G protein-coupled receptor, the adrenomedullin 2 receptor (AM2R) for the treatment on cancer.

Cumulus Oncology

The first oncology drug development accelerator in Europe. It develops new oncology treatments that target the unmet medical needs of specific cancer patient populations. A new company identity, business plans, infographic & presentations produced for Cumulus Oncology and it’s spin-out companies, Modulus Oncology and Nodus Oncology.  

The Prospect Model

Aims to increase access to services in a matched care approach in the NHS in Scotland, so that patients can get better access to GP and mental health services within the community. An identity produced for this NHS Lothian initiative. Several counselling and self-help manuals have also been produced.